Redeye comments on Enviro’s directed share issue of 150m shares, raising gross proceeds of SEK300m.
Redeye thinks Catella continues to perform decently in a very tough environment.
Redeye comments on Xspray Pharma following its Q1 2023 report.
Strong platform performance drove 19% org. growth Outlook remains strong – limited adj.
After positive pre-clinical results in rats with NEX-22 (for treatment of type 2 diabetes) in Q1, we...
Redeye comments on the new positive data from the second interim analysis of the ongoing phase Ib st...
Redeye’s view on the Q1 report. The trend continues to be weak as was indicated in the earlier profi...
Suominen's margins remained depressed in Q1, even though costs have passed their peak.
Redeye retains its positive view of Sdiptech following a Q1 report that exceeded our expectations.
Redeye update its fair value range following the announcement of a planned SEK450m rights issue in S...
Solid Q1 overall, New Gen games a bit soft Margin expansion to drive 12% EPS CAGR '23e-'25e Strong b...
Sales remain at a stable level, but we are cautious for H2 Cost inflation hurt Q1 margin, cost progr...
IRLAB has commented on statements in Ipsen’s 2022 Universal Registration Document regarding the clin...
Försenade ordrar stod för tillväxten i Q1. Ledningen satsar på tillväxt men med bakgrund mot en vika...
Movinn published on May 4th the companys Q1-report for 2023 and are showing progress.
Redeye comments on Invisio’s Q1-results which again was stronger than forecasted with revenue coming...
Redeye comments on Active Biotech’s Q1 report. After the end of Q1, results from naptumomab’s phase ...
Redeye retains its positive view of CombinedX following a strong Q1 showing solid organic growth and...
Ny vd och ordförande Efter börsens stängning meddelades att Philip Siberg tar över som vd och kliver...
Stark inledning på året med högsta förvaltningsresultat någonsin Totala hyresintäkter uppgick till c...
